Welcome to the November 2020 issue of Biopeople's Newsletter - the final issue

The Danish Life Science Cluster established

The Danish Life Science Cluster (DLSC) has been established as an association at the funding meeting on 24 November 2020. The Board constituted by companies, knowledge institutions and the Danish health care system looks forward to taking on the important task of contributing to and improving the basis for world class health care, innovation and product development for the benefit of growth and welfare. Please see the press release (in Danish) about the establishment of DLSC here.

Danish Life Science Cluster will build on the activities of the existing cluster organisations, including Biopeople, and about 30 employees from these organisations will staff the new cluster organisation, organised in four regional hubs.

Ida Sofie Jensen, CEO of the Danish Pharmaceutical Industry (Lif) will chair the Board of DLSC and Bjarke Bak Christensen, (Chair of Biopeople's Steering Committee), Head of Department of Biotechnology and Biomedicine, DTU, is appointed Vice Chairman of the DLSC Board.

Thank you for 15 exciting years

Due to the establishment of DLSC, the Biopeople secretariat closes down as of 31 December 2020, and it is time to say good bye after 15 years of operation!

We thank you so much for your contributions over the years. It has been a great pleasure to collaborate and network with all our members and other key stakeholders of the Biopeople Life Science community.

We now join forces with the DLSC partners and hope that many of our members and followers will take part in the future journey and activities, facilitating growth, innovative research and development.

In case you have any questions regarding the above, please do not hesitate to contact jane.nohr@biopeople.ku.dk, whose mail address will be open.

Read also

In this newsletter you will find news about biotech company NMD Pharma that moves into the Research Park INCUBA in Aarhus and learn about the CELIS project.

Also we present the key results from our member survey, conducted this fall.

Finally we have the pleasure to announce a few extra events in December.

We wish you a Merry Christmas and a prosperous New Year - with more hope, less COVID-19 and lots of innovative and collaborative activities.

Feedback to Biopeople

Earlier this fall we asked our member companies to give feedback regarding their needs and wishes for cluster activities, so that future cluster activities will be relevant and be of value to our members.

Strengthening the biotech community in Aarhus

When NMD Pharma moves into the Research Park INCUBA at Aarhus University Hospital, the company will contribute significantly to strengthening the biotech community in Aarhus.

NMD Pharma has received funding of more than 300 mill DKK for the development of new pharmaceuticals to treat neuromuscular diseases and expects high growth rates in the coming years.

CELIS combines some of the world-class life science ecosystems in Europe

CELIS is one of 13 European Strategic Cluster Partnerships for Excellence (ESCP-4x) selected under the European Cluster Excellence Programme as part of the European Commission’s COSME programme.


	Upcoming Biopeople events

Coexisting with the Microbiome - lessons and future trends - 3 December 2020

Photo by CDC on Unsplash

Bacteria, viruses, fungi, and bacteriophages coexist with us and interplay with each other in our bodies creating a complex and dynamic ecosystem.

Webinar: Is Danish Life Science Industry Green and Sustainable? - 9 December 2020

Photo by cleanimalist on Unsplash

More than 130 Danish Life Science companies have answered a survey on the state of digitalization and sustainability in the industry in Denmark.

Why you should use X-rays in formulation of biologics - 10 December 2020

In this webinar, you will be introduced to new possibilities for tests, trouble shooting, and investigations of drug formulations.

Webinar: The Emerging Influence of Digital Biomarkers on Healthcare - 18 December 2020

Digital biomarkers, omics technologies and behavioural interventions have a huge potential to improve treatment outcome for patients, but challenges around evidence generation, infrastructure, incentives, and workflow remain.